PHVS
Pharvaris NV

748
Loading...
Loading...
News
all
press releases
Pharvaris Reveals Positive HAE Drug Data
Pharvaris (PHVS) has released an update. Pharvaris, a biopharmaceutical company, has showcased promising data at the Bradykinin Symposium 2024 for...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Pharvaris (PHVS) and Stevanato Group (STVN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Silence Therapeutics (SLN Research Report), Pharvaris...
TipRanks Financial Blog·1y ago
News Placeholder
Morgan Stanley Sticks to Their Buy Rating for Pharvaris (PHVS)
In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Pharvaris (PHVS Research Report), with a price target of...
TipRanks Financial Blog·1y ago
News Placeholder
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
Globe Newswire·1y ago
News Placeholder
Pharvaris (PHVS, $21.64) Aroon Indicator entered a Downtrend on April 01, 2024.
For the last three days, A.I.dvisor has detected that PHVS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·1y ago
News Placeholder
Pharvaris (PHVS, $23.11) Aroon Indicator entered a Downtrend on March 28, 2024.
For the last three days, A.I.dvisor has detected that PHVS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·1y ago
News Placeholder
Pharvaris (PHVS, $23.5) Aroon Indicator entered a Downtrend on March 27, 2024.
For the last three days, A.I.dvisor has detected that PHVS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·1y ago
News Placeholder
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE attacks...
Globe Newswire·2y ago
News Placeholder
38,893 Shares in Pharvaris (NASDAQ:PHVS) Purchased by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP purchased a new position in Pharvaris (NASDAQ:PHVS Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities...
Zolmax·2y ago
News Placeholder
Pharvaris (PHVS, $23.45) Aroon Indicator entered a Downtrend on March 12, 2024.
For the last three days, A.I.dvisor has detected that PHVS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·2y ago

Latest PHVS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.